-Strengthened balance sheet with $1.8 million cash from new convertible debt in Q2 and additional $5.0 million through the sale of preferred stock after quarter end
-Converted $3.1 million outstanding note to preferred stock, further optimizing the balance sheet
SAN DIEGO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- DNA X, Inc. (Nasdaq: SONM) (“DNA X” or the “Company”), a developer of intelligent digital-asset technologies, today announced financial results for the second quarter ended June 30, 2026.
“The second quarter marked an important milestone as we secured the capital and resources necessary to advance our strategic priorities and position DNA X for its next phase of growth," said Mike Mulica, acting Chief Executive Officer. "With these transactions, we are enhancing our ability to execute on our vision, expand our exposure to the accelerating AI economy, creating long-term value for our shareholders.”
During the quarter, the Company raised $1.8 million cash through the issuance of a $3.1 million convertible note that cancelled an existing $1.3 million note. In July 2026, this $3.1 million note was cancelled and preferred stock was issued to the note holder for $6.00 per share. In July and August 2026, $5.0 million in cash was raised through the issuance of additional preferred stock at $6.00 per share. Each share of preferred stock can be converted to common shares on a one-for-one basis after stockholders’ approval is obtained.
The cash raised will be used to accelerate product and business development at DNA X.
Second Quarter 2026 Financial Highlights:
Revenue: There was no revenue from continuing operations because the AI trading platform was closed to the public during the quarter and legacy activities are included as discontinued operations. The Company expects revenue from the trading platform to begin towards the end of the third quarter 2026 or the beginning of the fourth quarter 2026.General & Administrative Expenses: Second-quarter general and administrative expenses from continuing operations were $1.3 million, which reflects the downsizing of the Company following the sale of the Company's legacy business.Cash Position: The Company ended the quarter with $0.9 million. Subsequent to June 30, 2026, the Company received $5.0 million in cash from the sale of preferred stock. This cash will be used for working capital purposes and to support and grow the DNA X trading platform business.
About DNA X, Inc. DNA X, Inc. (Nasdaq: SONM) operates an AI-driven trading platform that applies advanced artificial intelligence to automate trading strategies.
For more information, visit https://ir.dna-x.global.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to matters of historical fact are forward-looking statements, including, without limitation, statements regarding the Company’s strategic transformation, the expected growth, performance and market opportunities of the DNA X trading platform, and the Company’s future operations and financial performance.
These forward-looking statements are based on the Company’s current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: risks related to the Company’s ability to successfully integrate and operate the DNA X trading platform and achieve anticipated growth; the early-stage nature of the Company’s current business and the volatility of the cryptocurrency markets; the Company’s recent disposition of its mobile device design and manufacturing business; the Company’s ability to obtain or maintain sufficient liquidity to execute its business plan; potential delays or challenges in executing its strategic plans; general economic, market and industry conditions; and the Company’s ability to maintain compliance with Nasdaq listing requirements.
Additional information regarding these and other risks and uncertainties is included in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update such statements, except as required by law.
DNA X, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
June 30,
2026 December 31,
2025 (Unaudited) Assets Cash and cash equivalents $900 $1,303 Receivable for cash held back from the asset sale 1,248 — Receivable, related party 15 — Prepaid expenses and other current assets 759 676 Current assets held for sale — 26,930 Total Current assets 2,922 28,909 Investment in DNA X LLC under equity method — 1,242 Identifiable intangible assets 1,379 — Deferred tax assets — 1,441 Other assets 216 274 Non-current assets held for sale — 12,032 Total assets $4,517 $43,898 Liabilities and stockholders’ deficit Accounts payable 683 4,030 Accrued liabilities 960 704 Promissory note, net from related party 2,400 1,035 Promissory notes, net — 4,030 Derivative liability 797 171 Income tax payable 309 2,598 Current liabilities held for sale — 38,057 Total current liabilities 5,149 50,625 Deferred tax liability 600 — Total liabilities 5,749 50,625 Commitments and contingencies — — Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228 as of December 31, 2025 — 1,228 Stockholders’ deficit Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,488,268 and 1,265,067 shares issued and outstanding at June 30, 2026 and December 31, 2025 respectively* 1 1 Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at June 30, 2026 and December 31, 2025 — — Additional paid-in capital* 297,674 296,309 Accumulated deficit (298,907) (304,265)Total stockholders’ deficit (1,232) (7,955)Total liabilities, redeemable common stock, and stockholders’ deficit $4,517 $43,898 *Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025. DNA X, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)
Three Months Ended Six Months Ended June 30, June 30, 2026 2025 2026 2025 Continuing operations Net revenues $— $— $— $— Operating expenses General and administrative 1,278 1,471 4,896 2,341 Total operating expenses 1,278 1,471 4,896 2,341 Net loss from operations (1,278) (1,471) (4,896) (2,341)Interest expense, net (140) (389) (271) (480)Loss on remeasurement of derivative liability (11) — (238) — Gain on extinguishment of debt 191 — 191 — Equity income from DNA X LLC — — 48 — Net loss from continuing operations before income taxes (1,238) (1,860) (5,166) (2,821)Income tax benefit from continuing operations — — — — Net loss from continuing operations (1,238) (1,860) (5,166) (2,821)Discontinued operations Income (loss) from discontinued operations (9) (5,615) 10,259 (4,196)Net income (loss) $(1,247) $(7,475) $5,093 $(7,017)Net income (loss) per share basic and diluted: Continuing operations* $(0.91) $(3.52) $(3.95) $(6.61)Discontinued operations* $(0.01) $(10.63) $7.84 $(9.82)Net income* $(0.92) $(14.15) $3.89 $(16.43)Weighted-average shares used in computing net income (loss) per share: Basic 1,350,914 528,367 1,308,227 426,962 Diluted 1,350,914 528,367 1,308,227 426,962 *Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025.
Prada Group CEO Andrea Guerra speaks to CNBC's Charlotte Reed about global luxury consumers, keeping the brand innovative and relevant, AI in fashion, and why they wanted to design the next generation of astronauts' spacesuits. Subscribe: @CNBCInternationalLive Subscribe to CNBC International: @CNBCInternational LinkedIn: https://www.linkedin.com/showcase/cnbc-international/ TikTok: https://www.tiktok.com/@cnbci Facebook: https://www.facebook.com/cnbcinternational Instagram: https://www.instagram.com/cnbcinternational/ Threads: https://www.threads.net/@cnbcinternational X: https://twitter.com/CNBCi Telegram: https://t.me/cnbci
Ginkgo Bioworks NYSE: DNA reported second-quarter 2026 revenue of $20 million, down 48% from the year-earlier period, as the company continued to shift its focus toward autonomous laboratory systems, contract research services and related software.
Chief Executive Officer Jason Kelly said the company’s priorities for 2026 remain investing in autonomous labs, expanding its Nebula autonomous laboratory in Boston, and pursuing new sales to biopharma companies, national laboratories and research universities.
Get Ginkgo Bioworks alerts:
The company also reaffirmed its full-year cash-burn guidance of $125 million to $150 million. Ginkgo ended the quarter with $302 million in cash and cash equivalents, along with $87 million of restricted cash designated for certain customers and operating activities, Kelly said.
Financial Results and Cash Burn Chief Financial Officer Steve Coen said Ginkgo’s former Biosecurity business, which was divested in a transaction completed April 3, is classified as discontinued operations. Financial commentary for the quarter relates exclusively to continuing operations, which the company now reports as one segment.
Revenue totaled $40 million for the first six months of 2026, a 49% decline from the prior-year period. Coen noted that the first half of 2025 included $7.5 million of non-cash revenue related to the mutual termination of the BiomEdit agreement. Excluding that amount, first-half revenue declined about 42% year over year.
Research and development expense was $30 million, down 4% from $31 million a year earlier. General and administrative expense was $12 million, down 26% from $16 million in the prior-year quarter. Net loss from continuing operations was $57 million, compared with a $53 million loss a year earlier. Adjusted EBITDA was negative $36 million, compared with negative $25 million in the second quarter of 2025. Second-quarter cash burn was $45 million, compared with $38 million a year earlier. For the first half of 2026, cash burn was $93 million, down 3% from $96 million in the prior-year period. Coen said first-quarter cash burn included a $14 million payment to Google Cloud related to an amended 2025 commitment. The revised arrangement reduced future minimum commitments by more than $100 million and extended the commitment term to six years from three years, he said.
Adjusted EBITDA included $14 million in costs associated with excess leased space during the second quarter, up from $12 million a year earlier. Coen said those expenses consist of rent and related charges on unoccupied space, net of sublease income, and could potentially be reduced through additional subleasing.
Ginkgo raised $17 million through its at-the-market equity program during the quarter. The company excludes those proceeds from its cash-burn calculation.
Autonomous Lab Expansion Kelly said Ginkgo expanded Nebula, its Boston autonomous lab, to 105 racks after adding roughly 50 racks during the quarter. He said the expansion was installed and operating within approximately three weeks after the racks had been manufactured.
The system uses a track-and-robotic-arm configuration to move samples among laboratory devices. According to Kelly, Nebula operates continuously and on an average day can run about 30 unique protocols submitted by scientists, with more than 100 protocol copies across the system’s devices.
Kelly said Ginkgo is working to move a majority of its internal laboratory work to Nebula over time. The company expects the system to improve the economics of its service offerings while serving as a demonstration platform for prospective autonomous-lab customers.
He contrasted the company’s autonomous-lab approach with more conventional laboratory work cells, which can automate repeated tasks but generally lack flexibility for new experimental protocols. Kelly said Ginkgo is seeking to combine the continuous operation of automated systems with the flexibility of manual laboratory benches.
Government and University Projects Ginkgo said it is building an autonomous laboratory system for Pacific Northwest National Laboratory. Kelly said the company had previously installed the first 13 racks at the Department of Energy laboratory and expects the project to expand to a 97-rack system.
The company also said it was selected to build autonomous labs for MIT, Caltech, the University of Maryland and Northwestern University. Kelly said the Caltech, Maryland and Northwestern projects are part of a National Science Foundation program, while MIT’s project is funded through a separate grant.
Coen said revenue from large automation projects is generally recognized when equipment is delivered and installation is completed. He said the national laboratory project has generated some preliminary-contract revenue, but revenue from the larger installation will be recognized upon delivery and completion of installation.
In addition to equipment revenue, Coen said autonomous-lab contracts can include support, maintenance, custom work and software licensing revenue that may continue after installation.
Datapoints Services and Drug Discovery Offering Ginkgo also highlighted its Datapoints contract research offerings, including a recently launched service called ADME-One. The service provides a panel of five assays used to assess absorption, distribution, metabolism and excretion properties of small-molecule drug candidates.
Kelly said Ginkgo is offering the service for $199 per panel, compared with prices he cited of $2,000 to $5,000 from Western contract research organizations and $1,000 to $2,500 from Chinese providers. The offering includes partnerships with Inductive Bio for pharmacokinetic projections and Tangible Scientific for compound management, he said.
The company said it has conducted internal quality-control testing and comparisons with external vendors for the assays. Kelly also said Ginkgo plans to add plate-based chemistry, chemical purification and inert-atmosphere chemistry capabilities to its automated operations.
Coen said Datapoints revenue is recognized over time, similar to Ginkgo’s legacy services business. He said Datapoints projects are generally smaller than historical projects and typically run from three to nine months, though some can extend longer.
About Ginkgo Bioworks (NYSE:DNA)Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company's services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Ginkgo Bioworks Right Now?Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives August 05, 2026 07:25 ET | Source: Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company's long-term growth objectives.
The strategic review process will evaluate a range of alternatives that may strengthen the Company's position and accelerate value creation, including potential strategic partnerships, financing initiatives, business development opportunities, acquisitions, commercial collaborations, and other corporate transactions.
revyve® Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray have both received FDA 510(k) clearance in the United States and Health Canada approval. Commercial activities in both the US and Canada commenced in 2026 with the addition of key senior business development personnel.
Philip Renaud, Chairman of Kane Biotech, commented: “Over the past several years, Kane has built a differentiated position in biofilm science and advanced wound care while achieving important commercial and clinical milestones. The Board believes this is an appropriate time to undertake a disciplined review of strategic opportunities that may strengthen the Company’s position and enhance shareholder value. We are pleased to work with DNA Advisors as we evaluate potential opportunities and engage with parties that may support the next stage of Kane’s development.”
Dr. Robert Huizinga, Interim Chief Executive Officer of Kane Biotech, added: “We remain focused on executing our commercial objectives while simultaneously evaluating initiatives that have the potential to create additional value for shareholders. Kane has established a strong foundation through its scientific expertise, intellectual property portfolio, expanding commercial activities, and growing market awareness of biofilm management in wound care. This review process is intended to ensure that the Company is pursuing the opportunities that best position Kane for long-term success."
There can be no assurance that the strategic review process will result in any specific transaction or outcome. Kane has not established a timetable for completion of the review process and does not intend to disclose developments unless and until the Board of Directors has approved a specific course of action or disclosure is otherwise required by applicable securities laws.
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list here.
Presentation: Disrupting Biofilms to Save Limbs and Transform Wound Care
For more information:
Dr. Robert HuizingaRay DupuisInterim CEOChief Financial OfficerKane Biotech Inc.Kane Biotech [email protected]@kanebiotech.com(780) 970-1100(204) 298-2200
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
Caxton Associates LLP lowered its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) by 60.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,778 shares of the company's stock after selling 103,802 shares during the quarter. Caxton Associates LLP owned
Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced that its affiliate, EG BioMed US Inc., a Delaware corporation (“EG BioMed US”), has obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania for its CLIA-certified, CAP-accredited laboratory in Bothell, Washington (CLIA #50D2316600), reinforcing the Company’s transition from a collection of technologies to a platform-based biotechnology company anchored in clinically derived molecular data.
The Rhode Island license, issued May 13, 2026, covers the clinical genetics specialty, while the Pennsylvania permit, issued June 9, 2026, covers the clinical chemistry and hematology categories. Both jurisdictions are among the most tightly regulated in the United States. With these additions, the laboratory’s authorized multi-state operating footprint now extends to 46 U.S. states, plus Washington, D.C. and Guam.
This geographic expansion directly broadens patient access and supports the Company’s early cancer detection operations. Through the accredited laboratory and the EG Telehealth Platform, https://mdi.eg-bio.com, YD Bio supports blood-based testing services across pancreatic, colorectal, breast, liver, and other gastrointestinal cancers.
The Company views this commercial diagnostic activity primarily as early commercial validation and a critical source of real-world molecular data, rather than viewing the laboratory as a standard testing cost-center. Every addition of regulated jurisdictions to the platform’s reach accelerates the accumulation of high-quality data.
“Expanding our laboratory’s reach into additional, highly regulated states is meaningful in itself, but the more important story is what this engine makes possible,” said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio.
About EG BioMed US
EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed Co., Ltd., a Taiwan company (“EG BioMed”), and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio. As previously disclosed, YD Bio entered into a non-binding Memorandum of Understanding to merge with EG BioMed in January 2026; the proposed transaction is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals and the finalization of definitive agreements; however, there can be no assurance that the transaction will be consummated on the terms contemplated or within the anticipated timeline, if at all.
About YD Bio Limited
YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. The Company operates DNA methylation–based oncology testing programs in the United States under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. Through strategic partnerships and scalable execution capabilities, the Company aims to advance biomedical innovation with real-world clinical and commercial impact. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including, among others, statements about the Company’s strategy, ongoing transactions, and expected commercialization and regulatory timelines. Forward-looking statements are based on current expectations, estimates, forecasts, and projections and are not guarantees of future performance. Investors can identify these forward-looking statements by words or phrases such as “aim,” “target,” “approximates,” “believes,” “designed to,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Actual results may differ materially due to a variety of factors, including regulatory decisions and feedback, our ability to commercialize our products and services, our ability to consummate certain transactions and achieve their anticipated benefits, and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission (the “SEC”). The Company undertakes no obligation to update any forward-looking statements, except as required by law. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Annual Report on Form 20-F, registration statement and other filings with the SEC.
For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: [email protected]
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization. , /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1".
Volition Team Members Discuss Capture-Seq™ The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.
Dr Jake Micallef, Chief Scientific Officer, Volition commented:
"Distinguishing cancer derived plasma DNA from healthy DNA when the two are mixed is problematic. When the cancer DNA makes up 1% or less of the total DNA it is extremely problematic. Moreover, DNA from cancer and healthy cells has the same double helix structure and has never before been separated chemically.
"Our manuscript, submitted in November and previously announced in December 2025, described a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA.
"Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years.
"In this updated manuscript we report a new, two-step method for preparing pure circulating tumor DNA data sets for cancer patients:
i. physical enrichment of the sample and
ii. bioinformatic removal of virtually all remaining non-tumor cfDNA sequences from the DNA sequence data set.
"This new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA.
"These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers.
We call this technology "Capture-Seq™" and it shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease.
"Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."
Dr Andrew Retter, Medical Consultant, Volition commented:
"From a clinical perspective, the proof of concept and early blinded validation results reported in this paper are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional controls We are now working on a further validation cohort of early stage cancers, and expect this data soon.
"For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to multi-cancer early detection and disease management, particularly in combination with Volition's existing Nu.Q® assay for lung cancer (H3K27me3) but potentially in combination with other technologies too."
Mr. Gael Forterre, Chief Commercial Officer, Volition added:
"This scientific breakthrough has generated a lot of interest with potential licensing partners.
"We feel that this technology could, with further development, become very widely used, in both the human and potentially the veterinary market, not only for multi-cancer early detection but also the detection of Minimal Residual Disease.
"We believe this represents a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion2 for the human MCED use, and over $13 Billion2 for MRD.
"We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible."
The updated paper should be available on the preprint service Research Square in the coming days.
LINK TO Research Square Data on File : Volition TAM Model About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, [email protected] +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
Video - https://www.youtube.com/watch?v=R11jftp4Vcw
Among the strongest early performers of ViX Micros: "El Regreso de la Heredera Fugitiva" and Acábame, which surpassed 4 million views in its first week alone.
TelevisaUnivision
TelevisaUnivision is moving aggressively to turn its microdrama platform into a new growth engine, betting that the melodramatic storytelling that powered decades of telenovelas can be reshaped for mobile-first audiences in one- to two-minute vertical episodes.
In under a year, the company’s Spanish-language short-form vertical video offering has racked up 900 million social media views and 6 million daily users. For Rafael Urbina, president of streaming and digital at TelevisaUnivision, the numbers show the strategy is already working both as a user-acquisition tool and as a potential revenue stream.
“I do think this has the opportunity to become a multimillion-dollar business at scale,” Urbina says.
“We certainly have a first-mover advantage today. We have our own platform... so we own this end to end. We have the production capabilities. All the way through to the app that the consumer is holding in their hands, we control. That gives us an opportunity to monetize in a different way, to integrate in a different way. And it just presents a massive business opportunity for us.”
The company highlighted that opportunity at its Upfronts last year.
MORE FOR YOU
Adapting Telenovelas for The TikTok EraViX MicrO is built around scripted vertical series, with episodes running roughly 60 to 120 seconds and designed for phones, feeds and fast binges. Each micro-series averages about 60 episodes, all dropped at once in the ViX app so viewers can watch in quick bursts or marathon sessions.
The platform had been operating quietly since July 2025 and, by the time of its official launch announcement in February, had already produced more than 80 micro-series and released more than 50 of them.
For TelevisaUnivision, whose roots are in the telenovela genre, the compressed format is an update rather than a break from its core identity.
“The storytelling is very similar to our traditional storytelling across melodramas,” Urbina says. “They may amplify some of those patterns. It may be even more melodramatic and it’s certainly faster-paced. But the essential storytelling ingredients are there.”
A scene from the ViX MicrO "La Venganza de las Tóxicas."
TelevisaUnivision
Discovery starts on social platforms including YouTube, Instagram, TikTok, Facebook and X, where trailers and the first five episodes are posted to drive viewers into the app, where the rest of the series is available for free. While ViX remains focused on its core streaming platform, Urbina says microdramas are creating a new mobile-first habit among viewers who may already know the service but have not been using its app as their primary destination.
“The micros are engaging a disproportionate amount of new users,” Urbina says. “As a result, this is an opportunity for us to engage millions of people who have discovered the VIX streaming app on mobile but are primarily using it on connected TV.”
That funnel serves a dual purpose: it meets audiences where they already spend time while pulling them deeper into the broader ViX ecosystem. According to Urbina, ViX reaches about 50 million people across its apps, including mobile and connected TV. “On social, that number is much greater,” he says. “We reach hundreds of millions of people every single month.”
Building the MachineWhile Spanish-language competitor Telemundo has also moved into the microdrama space, Urbina says ViX’s edge lies in its ability to control the full stack, from production through distribution and monetization.
“We have a competitive advantage moving to this new format, in being able to produce this content at scale and cost-effectively,” Urbina says.
Backed by TelevisaUnivision’s infrastructure in Mexico, the ViX MicrO production machine is substantial. Episodes are produced in as little as five days, with more than 10 production teams running up to four series at once. More than 50 writers are developing stories for the platform, supported by over 450 on-camera talents drawn heavily from Televisa’s Centro de Educación Artística (CEA) as well as theater and other emerging talent.
Urbina sees the pipeline as a way to develop stars and stories for the broader company.
“We see a lot of potential there in identifying our next huge star across our traditional broadcast and streaming platforms by testing the grounds with this short-form content,” he says. “But it’s not only about the stars. It’s also about the stories.”
So far, TelevisaUnivision says it has produced about 80 micro-series and premiered about 50, with the platform logging 80 million minutes of viewing in its first year. Among the strongest early performers are El Regreso de la Heredera Fugitiva, Me Casé para Vengarme, Pero Me Enamoré, La Cocinera que Conquistó al Presidente and Acábame, which surpassed 4 million views in its first week alone.
The stories lean into classic melodrama territory — forbidden love, family betrayal, revenge and identity — with titles like Mi Padre Me Robó a Mi Novia, Isadora la Usurpadora and Mi Vida NO Es una Telenovela.
Rafael Urbina, TelevisaUnivision's president of streaming and digital, during a presentation of ViX Micro.
TelevisaUnivision
Monetizing the FormatMonetization today comes through in-stream ads, brand integrations, product placement and custom content. Urbina points to a branded series made for JCPenney as one example, with shoppable products built into the app experience. He also sees more revenue layers ahead.
“Obviously, at some point you will see some of this live either behind a subscription wall or behind some sort of a more gamified token system,” Urbina says. “And I think those are things that we’re actively experimenting with.”
ViX MicrO is also part of a broader scale play. The company plans to debut 100 original microdramas in 2026, supplemented by licensed content from other markets. Urbina says scale matters because viewers move through the format quickly and the catalog has to keep replenishing.
“Scale and availability of content is very important,” he says. “You need a very large content offering in order to engage those consumers and retain those consumers.”
A New PlaybookUrbina says ViX MicrO is built on a very different model from Quibi, the short-lived mobile venture that launched with big ambitions and collapsed within months. He argues Quibi failed because it leaned on expensive, star-driven, professionally produced horizontal video.
“Quibi, I think, from my experience with it — and I did spend some time with it — was horizontal video, professionally produced, very high production values, star power, very, very, very expensive to produce,” Urbina says.
“The premise was right,” he says. “But in how we address that market opportunity, this is completely different from what Quibi tried to do a few years ago.”
ViX MicrO, by contrast, is built on one- to two-minute episodes, cliffhangers, lean costs and relatively unknown talent.
AI as an AcceleratorUrbina also sees generative AI as a practical production tool rather than a creative threat.
“I think you can look at generative AI today as almost one more camera,” he says. “We can use it to create backgrounds.”
He says AI can also help with localization, including dubbing and translation for licensed content, while keeping the cost structure competitive.
“This is a different model than our traditional linear model,” Urbina says. “So the cost structure is very, very important. I think Gen AI is going to allow us to remain very competitive and make this very profitable for us.”
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) major shareholder Barry Canton sold 13,116 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $6.40, for a total transaction of $83,942.40. Following the completion of the sale, the insider owned 338,568 shares in the company, valued at $2,166,835.20. This represents a 3.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Barry Canton also recently made the following trade(s):
On Wednesday, April 8th, Barry Canton sold 13,155 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $6.93, for a total transaction of $91,164.15. Ginkgo Bioworks Price Performance Shares of Ginkgo Bioworks stock opened at $6.46 on Monday. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.37 and a fifty-two week high of $17.58. The firm has a market capitalization of $399.76 million, a P/E ratio of -1.14 and a beta of 1.56. The company’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $9.48.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last issued its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. Ginkgo Bioworks had a negative net margin of 183.81% and a negative return on equity of 52.82%. The firm had revenue of $33.40 million for the quarter, compared to analyst estimates of $37.57 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.
Analyst Upgrades and Downgrades A number of brokerages have recently commented on DNA. TD Cowen cut their price target on shares of Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. Finally, BTIG Research cut their price target on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $8.50.
Check Out Our Latest Stock Analysis on DNA
Trending Headlines about Ginkgo Bioworks Here are the key news stories impacting Ginkgo Bioworks this week:
Positive Sentiment: March short interest fell sharply — short interest totaled 6,146,646 shares as of March 31, down 23.2% from 8,004,118 on March 15; roughly 11.0% of the float is sold short and the days-to-cover is ~5.2. Reduced short exposure can remove a headwind and support the stock. Negative Sentiment: Large insider sales by the CEO: Jason R. Kelly sold 97,015 shares on April 8 (avg $6.93) and 109,767 shares on April 9 (avg $6.40), totaling ~206,782 shares (~$1.37M) and materially reducing his holdings. The filings say the sales were to cover tax withholding on vested equity. Jason R. Kelly Form 4 Negative Sentiment: Other insiders/major holders also sold small blocks (Reshma P. Shetty and Barry Canton each sold ~13k shares on April 8–9 at similar prices). These rounds of sales were likewise disclosed as tax-withholding-related. Reshma’s filing: Reshma P. Shetty Form 4; Barry Canton’s filing: Barry Canton Form 4 Hedge Funds Weigh In On Ginkgo Bioworks A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Ginkgo Bioworks by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock worth $36,166,000 after purchasing an additional 99,379 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of Ginkgo Bioworks by 10.0% during the third quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock worth $32,076,000 after purchasing an additional 200,000 shares during the period. Legal & General Group Plc raised its stake in Ginkgo Bioworks by 7.9% during the third quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock worth $23,458,000 after buying an additional 118,402 shares during the last quarter. Millennium Management LLC lifted its holdings in Ginkgo Bioworks by 113.1% in the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock valued at $8,137,000 after buying an additional 757,535 shares during the period. Finally, State Street Corp lifted its holdings in Ginkgo Bioworks by 38.4% in the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock valued at $10,737,000 after buying an additional 358,231 shares during the period. Institutional investors and hedge funds own 78.63% of the company’s stock.
About Ginkgo Bioworks (Get Free Report)
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
See Also Five stocks we like better than Ginkgo Bioworks
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEInsider Selling: Spire Global (NYSE:SPIR) Chairman Sells $22,422.45 in Stock
NEXT HEADLINE »Spire Global (NYSE:SPIR) CEO Sells $161,462.76 in Stock
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) insider Reshma Shetty sold 13,155 shares of the stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $6.93, for a total value of $91,164.15. Following the completion of the sale, the insider owned 351,684 shares of the company’s stock, valued at $2,437,170.12. The trade was a 3.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ginkgo Bioworks Stock Up 0.1% DNA opened at $6.46 on Monday. The stock has a fifty day moving average of $7.63 and a 200-day moving average of $9.48. The firm has a market capitalization of $399.76 million, a P/E ratio of -1.14 and a beta of 1.56. Ginkgo Bioworks Holdings, Inc. has a 12-month low of $5.37 and a 12-month high of $17.58.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. The company had revenue of $33.40 million during the quarter, compared to analyst estimates of $37.57 million. Ginkgo Bioworks had a negative return on equity of 52.82% and a negative net margin of 183.81%. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.
More Ginkgo Bioworks News Here are the key news stories impacting Ginkgo Bioworks this week:
Positive Sentiment: March short interest fell sharply — short interest totaled 6,146,646 shares as of March 31, down 23.2% from 8,004,118 on March 15; roughly 11.0% of the float is sold short and the days-to-cover is ~5.2. Reduced short exposure can remove a headwind and support the stock. Negative Sentiment: Large insider sales by the CEO: Jason R. Kelly sold 97,015 shares on April 8 (avg $6.93) and 109,767 shares on April 9 (avg $6.40), totaling ~206,782 shares (~$1.37M) and materially reducing his holdings. The filings say the sales were to cover tax withholding on vested equity. Jason R. Kelly Form 4 Negative Sentiment: Other insiders/major holders also sold small blocks (Reshma P. Shetty and Barry Canton each sold ~13k shares on April 8–9 at similar prices). These rounds of sales were likewise disclosed as tax-withholding-related. Reshma’s filing: Reshma P. Shetty Form 4; Barry Canton’s filing: Barry Canton Form 4 Institutional Trading of Ginkgo Bioworks Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Ginkgo Bioworks by 4.2% during the third quarter. Vanguard Group Inc. now owns 2,480,504 shares of the company’s stock worth $36,166,000 after acquiring an additional 99,379 shares in the last quarter. Erste Asset Management GmbH raised its holdings in shares of Ginkgo Bioworks by 10.0% during the third quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock worth $32,076,000 after acquiring an additional 200,000 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Ginkgo Bioworks by 7.9% during the third quarter. Legal & General Group Plc now owns 1,608,923 shares of the company’s stock worth $23,458,000 after acquiring an additional 118,402 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Ginkgo Bioworks by 113.1% during the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock worth $8,137,000 after acquiring an additional 757,535 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Ginkgo Bioworks by 38.4% during the fourth quarter. State Street Corp now owns 1,292,071 shares of the company’s stock worth $10,737,000 after acquiring an additional 358,231 shares in the last quarter. 78.63% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth A number of analysts have recently issued reports on DNA shares. Wall Street Zen upgraded Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. TD Cowen reduced their target price on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, January 8th. BTIG Research reduced their target price on Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating for the company in a report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Ginkgo Bioworks has an average rating of “Reduce” and an average price target of $8.50.
Read Our Latest Research Report on DNA
Ginkgo Bioworks Company Profile (Get Free Report)
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
See Also Five stocks we like better than Ginkgo Bioworks
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECountry Trust Bank Has $76.40 Million Position in JPMorgan Chase & Co. $JPM
NEXT HEADLINE »Insider Selling: Spire Global (NYSE:SPIR) Chairman Sells $21,840.34 in Stock
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) major shareholder Barry Canton sold 13,155 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $6.93, for a total value of $91,164.15. Following the sale, the insider directly owned 351,684 shares in the company, valued at $2,437,170.12. The trade was a 3.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Barry Canton also recently made the following trade(s):
On Thursday, April 9th, Barry Canton sold 13,116 shares of Ginkgo Bioworks stock. The shares were sold at an average price of $6.40, for a total value of $83,942.40. Ginkgo Bioworks Trading Up 0.1% NYSE DNA opened at $6.46 on Monday. The stock’s 50 day moving average is $7.63 and its two-hundred day moving average is $9.48. The company has a market capitalization of $399.76 million, a price-to-earnings ratio of -1.14 and a beta of 1.56. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.37 and a 1-year high of $17.58.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. The company had revenue of $33.40 million for the quarter, compared to the consensus estimate of $37.57 million. Ginkgo Bioworks had a negative return on equity of 52.82% and a negative net margin of 183.81%. On average, analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.
Trending Headlines about Ginkgo Bioworks Here are the key news stories impacting Ginkgo Bioworks this week:
Positive Sentiment: March short interest fell sharply — short interest totaled 6,146,646 shares as of March 31, down 23.2% from 8,004,118 on March 15; roughly 11.0% of the float is sold short and the days-to-cover is ~5.2. Reduced short exposure can remove a headwind and support the stock. Negative Sentiment: Large insider sales by the CEO: Jason R. Kelly sold 97,015 shares on April 8 (avg $6.93) and 109,767 shares on April 9 (avg $6.40), totaling ~206,782 shares (~$1.37M) and materially reducing his holdings. The filings say the sales were to cover tax withholding on vested equity. Jason R. Kelly Form 4 Negative Sentiment: Other insiders/major holders also sold small blocks (Reshma P. Shetty and Barry Canton each sold ~13k shares on April 8–9 at similar prices). These rounds of sales were likewise disclosed as tax-withholding-related. Reshma’s filing: Reshma P. Shetty Form 4; Barry Canton’s filing: Barry Canton Form 4 Institutional Inflows and Outflows Institutional investors and hedge funds have recently modified their holdings of the business. Erste Asset Management GmbH boosted its holdings in shares of Ginkgo Bioworks by 10.0% in the 3rd quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock worth $32,076,000 after acquiring an additional 200,000 shares in the last quarter. Jump Financial LLC acquired a new position in shares of Ginkgo Bioworks in the 2nd quarter worth approximately $4,163,000. Allianz Asset Management GmbH acquired a new position in shares of Ginkgo Bioworks in the 3rd quarter worth approximately $2,802,000. SPX Gestao de Recursos Ltda bought a new position in Ginkgo Bioworks in the 3rd quarter worth approximately $1,458,000. Finally, Green Alpha Advisors LLC raised its position in Ginkgo Bioworks by 10.6% in the 4th quarter. Green Alpha Advisors LLC now owns 14,327 shares of the company’s stock worth $119,000 after purchasing an additional 1,378 shares during the last quarter. 78.63% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes DNA has been the topic of a number of recent research reports. BTIG Research decreased their price objective on Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a report on Thursday, March 12th. TD Cowen reduced their target price on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $8.50.
Get Our Latest Report on DNA
Ginkgo Bioworks Company Profile (Get Free Report)
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
See Also Five stocks we like better than Ginkgo Bioworks
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEInsider Selling: Spire Global (NYSE:SPIR) CTO Sells $108,817.21 in Stock
NEXT HEADLINE »Primoris Services (NYSE:PRIM) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) insider Reshma Shetty sold 124,727 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $6.43, for a total value of $801,994.61. Following the completion of the transaction, the insider directly owned 436,422 shares in the company, valued at approximately $2,806,193.46. The trade was a 22.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Ginkgo Bioworks Trading Up 3.7% DNA stock opened at $6.69 on Tuesday. The firm has a 50 day simple moving average of $7.58 and a 200-day simple moving average of $9.45. The company has a market capitalization of $414.00 million, a P/E ratio of -1.18 and a beta of 1.56. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.37 and a twelve month high of $17.58.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.42) EPS for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.38. The firm had revenue of $33.40 million for the quarter, compared to the consensus estimate of $37.57 million. Ginkgo Bioworks had a negative net margin of 183.81% and a negative return on equity of 52.82%. On average, research analysts predict that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.
Institutional Inflows and Outflows Institutional investors have recently added to or reduced their stakes in the stock. Erste Asset Management GmbH lifted its stake in Ginkgo Bioworks by 10.0% in the third quarter. Erste Asset Management GmbH now owns 2,200,000 shares of the company’s stock valued at $32,076,000 after buying an additional 200,000 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $2,802,000. SPX Gestao de Recursos Ltda acquired a new position in Ginkgo Bioworks during the 3rd quarter valued at about $1,458,000. Savant Capital LLC grew its position in Ginkgo Bioworks by 7.9% in the 3rd quarter. Savant Capital LLC now owns 17,509 shares of the company’s stock worth $255,000 after purchasing an additional 1,276 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Ginkgo Bioworks in the 4th quarter worth about $166,000. 78.63% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth A number of research analysts have commented on the company. TD Cowen reduced their target price on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research lowered their target price on shares of Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating for the company in a research note on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $8.50.
Get Our Latest Research Report on Ginkgo Bioworks
About Ginkgo Bioworks (Get Free Report)
Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.
The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.
Read More Five stocks we like better than Ginkgo Bioworks
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Completed acquisition of the DNA X cryptocurrency trading platformClosed sale of the Company's mobile device assets to NEXA in January 2026Focused on enhancing the DNA X trading platform to prepare the platform for its initial growth phaseSan Diego, California--(Newsfile Corp. - April 14, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the fourth quarter and full year ended December 31, 2025.
The company purchased the DNA X cryptocurrency trading platform business in December 2025, following the launch of the DNA X.us website in November 2025 that is now active. The platform is designed to take advantage of movements between pairs of cryptocurrencies and to allow clients to automate trading strategies that automatically take advantage of converging and diverging pairs of cryptocurrency values.
The Company completed the sale of its mobile device design and manufacturing business to NEXA Mobility, a private company in the hardware space on January 23, 2026. The sale allows the Company to focus on the DNA X trading platform and its growth potential. The purchase price of the assets was $15 million less customary working capital adjustments with $13.5 million being paid immediately and $1.5 million in cash to be paid in nine months. The company used the proceeds to repay debt and other obligations. The remaining cash will be used to support the DNA X trading business.
On January 23, 2026, the Company successfully rebranded itself as DNA X, Inc., from Sonim Technologies Inc. The stock ticker on Nasdaq remains SONM and our primary corporate offices remain in San Diego.
On January 30, 2026, our Chief Executive Officer and board member resigned and our Executive Chairman became the acting Chief Executive Officer. A new board member, Scott Walker, a co-founder of DNA Holdings (the company that sold us the DNA X trading platform), was appointed to the board on January 30, 2026. Scott brings vast expertise in the cryptocurrency trading industry.
"We have transitioned to an industry that we believe is in its infancy and provides us with great opportunities for growth," said Mike Mulica, acting Chief Executive Officer. "We are very excited about the growth opportunity that we see in front of us."
Fourth Quarter 2025 Financial Highlights:
Revenue: There was no revenue from continuing operations because revenue from our phone and hotspot operations was included in discontinued operations.General & Administrative Expenses: Fourth-quarter general and administrative expenses for continuing operations were $1.2 million and were primarily due to legal costs for the acquisition of the DNA X trading platform, legal costs for the asset sale, and proxy costs for the special stockholders' vote for the asset sale. Cash Position: We ended the year with $1.3 million in cash from continuing operations. This cash plus cash proceeds from the asset sale will be used to support and grow the DNA X trading business.2025 Business Highlights: We successfully purchased the DNA X trading platform and we positioned the Company to complete the sale of our mobile device assets in January 2026. These transitions allowed us to move away from the geo-political risks that drastically raised the costs to produce our phones and hotspots as we moved our production outside of China, became subject to tariffs, and as supply chain costs increased. Notable accomplishments include:
Integrated the DNA X trading business with our existing infrastructureBegan the integration of our phone and hotspot business with the Buyer to achieve a desired sale price for the asset sale that we completed in January 2026Developed a transition plan to ensure that we have necessary leadership and expertise to manage the DNA X trading business once the phone and hotspot assets were sold2026 Outlook: "We expect future growth in revenue, gross margin and profitability as we exit the monitoring and testing phase and begin marketing our trading platform to the public," said Clay Crolius, CFO of DNA X. "With product enhancements and an increase in the number of cryptocurrencies that can be traded, we believe we are uniquely positioned to grow while increasing our margins."
About DNA X, Inc. DNA X operates a decentralized finance (DeFi) protocol that automates trading on decentralized exchanges, including recurring and limit orders. For more information, visit https://ir.dna-x.global.
Media and Investor Relations Contact: Clay Crolius, DNA X, Inc. [email protected].
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to matters of historical fact are forward-looking statements, including, without limitation, statements regarding the Company's strategic transformation, the expected growth, performance and market opportunities of the DNA X trading platform, anticipated use of proceeds from the sale of the Company's mobile device design and manufacturing business, and the Company's future operations and financial performance.
These forward-looking statements are based on the Company's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to successfully integrate and operate the DNA X trading platform and achieve anticipated growth; the early-stage nature of the Company's current business and the volatility of the cryptocurrency markets; the Company's recent disposition of its mobile device design and manufacturing business; the Company's ability to obtain or maintain sufficient liquidity to execute its business plan; potential delays or challenges in executing its strategic plans; general economic, market and industry conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.
Additional information regarding these and other risks and uncertainties is included in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update such statements, except as required by law.
DNA X, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2025 and 2024
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
December 31, 2025
December 31, 2024
Assets
Cash and cash equivalents$1,303
$5,343
Prepaid expenses and other current assets
676
-
Current assets held for sale
26,930
26,822
Total Current assets
28,909
32,165
Investment in DNA X, LLC
1,242
-
Deferred tax assets
1,441
64
Other assets
274
384
Non-current assets held for sale
12,032
7,126
Total assets$43,898
$39,739
Liabilities and stockholders' deficit
Accounts payable
4,030
738
Accrued liabilities
704
250
Promissory notes, net
5,065
-
Derivative liability on convertible note
171
-
Current liabilities held for sale
38,057
42,752
Total current liabilities
48,027
43,740
Income tax payable
2,598
1,699
Total liabilities
50,625
45,439
Commitments and contingencies
-
-
Redeemable common stock, $0.001 par value; 223,201 shares issued and outstanding; redemption value $1,228
1,228
-
Stockholders' deficit
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 and 276,881 shares issued and outstanding at December 31, 2025 and 2024, respectively*
1
-
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at December 31, 2025 and 2024
-
-
Additional paid-in capital*
296,309
277,908
Accumulated deficit
(304,265)
(283,608)Total stockholders' deficit
(7,955)
(5,700)Total liabilities, redeemable common stock, and stockholders' deficit$43,898
$39,739
* Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025. DNA X, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2025 and 2024
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
2025
2024
Continuing operations:
Net revenues$-
$-
Cost of revenues
-
-
Gross profit
-
-
Operating expenses
General and administrative
5,406
3,100
Other
-
-
Total operating expenses
5,406
3,100
Net income (loss) from operations
(5,406)
(3,100)Interest expense, net
(1,486)
(29)Loss on extinguishment of debt
(161)
-
Other income (expense), net
(902)
246
Net loss from continuing operations before income taxes
(7,955)
(2,883)Income tax expense from continuing operations
-
-
Net loss from continuing operations
(7,955)
(2,883)Discontinued Operations:
Loss from discontinued operations, net of tax
(12,702)
(30,765)Net loss$(20,657)$(33,648)Net loss per share basic and diluted:
Continuing operations*
(11.00)
(11.00)Discontinued operations*
(17.58)
(117.37)Net loss*$(28.58)$(128.37)Weighted-average shares used in computing net loss per share:
Basic and diluted*
722,689
262,118
* Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292277
Source: DNA X, Inc. (formerly Sonim Technologies Inc.)
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026
, /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET.
The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.
To ask a question ahead of the presentation, please submit them to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected].
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
, /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.
First Quarter 2026 Financial Results
As previously announced, Ginkgo completed the divestiture of its Biosecurity business on April 3, 2026 and is presenting the financial results of operations for the former business within discontinued operations. Accordingly, Ginkgo's previously reported financial results for comparable periods have been retrospectively recast to conform to this presentation and reflect Ginkgo as a single reporting segment. First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities. First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period. First quarter 2026 Adjusted EBITDA of $(42) million, down from $(44) million in the comparable prior year period. Cash, cash equivalents and marketable securities balance as of March 31, 2026 of $373 million. "We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."
Recent Business Highlights & Strategic Positioning
We believe that autonomous labs will replace the bench. The return on investment of the autonomous lab is clear for customers, with millions of square feet and tens of billions per year being spent on work happening at the lab bench The autonomous lab is a machine that can run 24/7 and can be seamlessly integrated into emerging AI models Nebula, our autonomous lab, is showing what is possible at the bleeding edge. Nebula is the world's largest autonomous lab and in 2026 we are aiming to double its size Recent coverage positions Ginkgo at the frontier of scientific innovation in the scientific (Nature), trade (R&D World), mainstream (Forbes, The Washington Post), and tech press (Sequoia's Training Data, TBPN) Policymakers and heads of R&D visit for our internal demonstrations. During SLAS 2026, over 500 visitors came to tour Nebula Cloud Lab, Datapoints, and Solutions are our version of Starlink. They both create revenue and speed the development of the autonomous lab We are seeing traction with our Cloud Lab from partners such as ProQR and Amazon, who included us as an integrated wet lab partner on their Amazon Bio Discovery platform Full Year 2026 Outlook
Ginkgo reaffirms expected total cash burn of $(150)-$(125) million in 2026. Conference Call Details
Ginkgo will host a videoconference today, Thursday, May 7, beginning at 4:30 p.m. ET. The presentation will include an overview of the first quarter 2026, recent business updates, a discussion on Ginkgo's outlook, as well as a moderated question and answer session.
To ask a question ahead of the presentation, please submit your questions to @Ginkgo on X (hashtag #GinkgoResults) or by sending an e-mail to [email protected].
A webcast link is available on Ginkgo's Investor Relations website and a replay will be made available following the presentation.
If you experience technical difficulties with any of these dial-ins or if you need international dial-in numbers, please visit our website at https://investors.ginkgobioworks.com/events/ for updated dial-in information.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release, the presentation, and the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, including with respect to technology adaptations to meet our customers' needs and the integration of our autonomous lab platform with third-party artificial intelligence models, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the timing for attaining Adjusted EBITDA breakeven, potential customer success, including successful application of our offerings by our customers, expected benefits from our strategic partnerships and collaborations (including with named partners such as ProQR and Amazon), the anticipated growth, scaling, capacity, capabilities and competitive position of our autonomous lab (including Nebula) and of our Cloud Lab, Datapoints and Solutions offerings, our beliefs and estimates regarding the size, composition, growth and pace of adoption of the market for autonomous laboratory and related services (including the displacement of manual laboratory work), expectations regarding the development, performance and future enhancements of our platform, and expectations with regard to revenue, including our ability to meet all milestones and achieve the maximum revenue available under certain of our customer arrangements, expenses, our full year 2026 outlook including the total cash burn guidance, and the market environment, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," "target," "goal," "aim," "design," "forecast," "outlook," "guidance," "seek" "position," and similar expressions, as well as the negatives of such terms. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown, (xiv) our ability to scale, expand the capacity of, and continue to develop the capabilities of our autonomous lab (including Nebula) on the timelines and to the extent we anticipate, (xv) the pace and degree to which autonomous laboratory infrastructure is adopted by, and displaces manual laboratory work in, the broader life sciences and industrial biotechnology markets, (xvi) the actual size, composition and growth of the addressable markets we target, which may differ materially from our estimates, (xvii) our ability to integrate our autonomous lab platform with third-party artificial intelligence models and other technologies, and the rate of development and adoption of such technologies, and (xviii) our ability to maintain and expand strategic partnerships and customer relationships, including those with named partners referenced in this release. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
Use of Non-GAAP Financial Measures
Certain of the financial measures included in this release, including Adjusted EBITDA, cash flow and cash burn, have not been prepared in accordance with generally accepted accounting principles ("GAAP"), and constitute "non-GAAP financial measures" as defined by the SEC. Ginkgo has included these non-GAAP financial measures because it believes they provide an additional tool for investors to use in evaluating Ginkgo's financial performance and prospects. Due to the nature and/or size of the items being excluded, such items do not reflect future gains, losses, expenses or benefits and are not indicative of our future operating performance. These non-GAAP financial measures are supplemental to, and should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the reconciliation below for additional information regarding certain of the non-GAAP financial measures included in this release, including a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo's most comparable GAAP financial measures. Ginkgo does not reconcile its forward-looking non-GAAP financial measures to the corresponding GAAP measures, due to variability and difficulty in making accurate forecasts and projections and/or certain information not being ascertainable or accessible; and because not all of the information, such as unrealized equity gains and losses necessary for a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure, can be predicted with reasonable accuracy and is available to Ginkgo without unreasonable efforts. For the same reasons, Ginkgo is unable to address the probable significance of the unavailable information. Ginkgo provides non-GAAP financial measures that it believes will be achieved, however it cannot accurately predict all of the components of the adjusted calculations and the GAAP measures may be materially different than the non-GAAP measures.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
[email protected]
MEDIA CONTACT:
[email protected]
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share data)
As of March 31,
2026
As of December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$ 143,864
$ 167,202
Marketable securities
229,592
255,418
Accounts receivable, net
19,815
24,026
Accounts receivable - related parties
454
229
Prepaid expenses and other current assets
16,230
24,963
Total current assets
409,955
471,838
Property, plant and equipment, net
163,020
167,371
Operating lease right-of-use assets
353,804
360,918
Investments
14,703
15,066
Intangible assets, net
48,860
53,482
Other non-current assets
39,522
47,167
Assets held for sale
3,211
3,854
Total assets
$ 1,033,075
$ 1,119,696
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
$ 16,309
$ 10,566
Deferred revenue (includes $98 and $98 from related parties)
14,910
18,946
Accrued expenses and other current liabilities
48,376
66,458
Total current liabilities
79,595
95,970
Non-current liabilities:
Deferred revenue, net of current portion (includes $64,810 and $64,787 from related
parties)
77,895
75,182
Operating lease liabilities, non-current
410,700
417,078
Other non-current liabilities
21,732
22,876
Total liabilities
589,922
611,106
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued
—
—
Common stock, $0.0001 par value (Note 8)
6
6
Additional paid-in capital
6,674,860
6,657,053
Accumulated deficit
(6,232,907)
(6,150,320)
Accumulated other comprehensive income
1,194
1,851
Total stockholders' equity
443,153
508,590
Total liabilities and stockholders' equity
$ 1,033,075
$ 1,119,696
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share data)
Three Months Ended March
31,
2026
2025
Revenue (1)
$ 19,474
$ 38,230
Costs and operating expenses:
Cost of other revenue
3,098
4,090
Research and development
49,920
70,923
General and administrative
37,830
39,723
Restructuring charges
—
4,466
Total operating expenses
90,848
119,202
Loss from operations
(71,374)
(80,972)
Other income (expense):
Interest income, net
3,596
6,081
Loss on investments
(1,214)
(3,693)
Other expense, net
(7,147)
(4,638)
Total other expense
(4,765)
(2,250)
Loss from continuing operations before income taxes
(76,139)
(83,222)
Income tax (benefit) expense
(80)
88
Net loss from continuing operations
$ (76,059)
$ (83,310)
Net loss from discontinued operations, net of tax
(6,528)
(7,647)
Net loss
$ (82,587)
$ (90,957)
Net loss per share:
Basic from continuing operations
$ (1.28)
$ (1.54)
Basic from discontinued operations
(0.11)
(0.14)
Basic
$ (1.39)
$ (1.68)
Weighted average common shares outstanding:
Basic
59,563,454
54,241,619
Comprehensive loss:
Net loss
(82,587)
(90,957)
Other comprehensive (loss) income:
Foreign currency translation adjustment
(579)
849
Unrealized gains (loss) on available-for-sale securities
(78)
107
Total other comprehensive (loss) income
(657)
956
Comprehensive loss
$ (83,244)
$ (90,001)
(1) includes related party revenue of zero and $8,098 for the three months ended March 31, 2026 and 2025, respectively.
Ginkgo Bioworks Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
Three Months Ended March 31,
2026
2025
Cash flows from operating activities:
Net loss from continuing operations
$ (76,059)
$ (83,310)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
12,799
14,822
Stock-based compensation
15,853
17,386
Loss on investments
1,214
3,693
Change in fair value of notes receivable
6,759
5,285
Change in fair value of contingent consideration
—
(1,302)
Non-cash lease expense
7,114
7,379
Accretion of discount on marketable securities
(120)
—
Other non-cash activity
185
149
Changes in operating assets and liabilities:
Accounts receivable
(242)
(667)
Prepaid expenses and other current assets
5,930
(581)
Operating lease right-of-use assets
—
3,675
Other non-current assets
94
(167)
Accounts payable, accrued expenses and other current liabilities
(11,601)
8,869
Deferred revenue, current and non-current (includes zero and $(7,878) from related
parties)
(2,606)
(13,190)
Operating lease liabilities, current and non-current
(4,995)
(4,790)
Other non-current liabilities
(758)
—
Net cash used in operating activities - continuing operations
(46,433)
(42,749)
Net cash used in operating activities - discontinued operations
(253)
(8,772)
Net cash used in operating activities
(46,686)
(51,521)
Cash flows from investing activities:
Purchases of marketable debt securities
(83,161)
(191,182)
Maturities of marketable debt securities
108,178
—
Purchases of property and equipment
(1,933)
(7,622)
Other
48
120
Net cash provided by (used in) investing activities
23,132
(198,684)
Cash flows from financing activities:
Principal payments on finance leases
(19)
(207)
Net cash used in financing activities
(19)
(207)
Effect of foreign exchange rates on cash and cash equivalents
(129)
74
Net decrease in cash, cash equivalents and restricted cash
(23,702)
(250,338)
Cash and cash equivalents, beginning of period
167,202
561,572
Restricted cash, beginning of period
45,169
44,171
Cash, cash equivalents and restricted cash, beginning of period
212,371
605,743
Cash and cash equivalents, end of period
143,864
312,420
Restricted cash, end of period
44,805
42,985
Cash, cash equivalents and restricted cash, end of period
$ 188,669
$ 355,405
The following table presents summary results of the Company's reportable segment, including significant expenses, and a reconciliation to loss from continuing operations before income taxes (in thousands):
Three Months Ended March 31,
2026
2025
Revenue
$ 19,474
$ 38,230
Costs and operating expenses:
Cost of other revenue (1)
2,672
3,121
Research and development (1)
30,105
48,670
General and administrative (1)
12,723
19,654
Stock-based compensation (2)
16,708
17,713
Depreciation and amortization
12,799
14,822
Restructuring charges (3)
—
4,466
Carrying cost of excess space (net of sublease income) (4)
15,842
11,674
Merger and acquisition related expense (income) (5)
—
(918)
Other (income) expense, net (6)
4,764
2,250
Loss from continuing operations before income taxes
$ (76,139)
$ (83,222)
(1)
The costs and operating expenses exclude expenses which are separately captioned below.
(2)
Includes $0.9 million and $0.4 million in employer payroll taxes for three months ended March 31, 2026 and 2025, respectively.
(3)
See Note 3, Restructuring, for composition of costs.
(4)
The carrying cost of excess space includes base rent, common area maintenance charges, and real estate taxes associated with facilities the Company is not occupying, net of any sublease income from these spaces.
(5)
Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs.
(6)
Includes interest income, interest expense, loss on investments, changes in fair value of certain assets and liabilities, and other gains and losses.
Three Months Ended March 31,
(in thousands)
2026
2025
Net loss from continuing operations (1)
$ (76,059)
$ (83,310)
Interest income, net
(3,596)
(6,081)
Income tax (benefit) expense
(80)
88
Depreciation and amortization
12,799
14,822
EBITDA
(66,936)
(74,481)
Stock-based compensation (2)
16,708
17,713
Restructuring charges (3)
—
4,466
Merger and acquisition related (income) expense (4)
—
(918)
Loss (gain) on investments
1,214
3,693
Change in fair value of notes receivable
6,759
5,285
Adjusted EBITDA
$ (42,255)
$ (44,242)
(1)
All periods include non-cash revenue when earned, including $7.5 million recognized in the three months ended March 31, 2025, pursuant to the release of deferred revenue related to the mutual termination of a customer agreement.
(2)
Includes $0.9 million and $0.4 million in employer payroll taxes for the three months ended March 31, 2026 and 2025, respectively.
(3)
Restructuring charges primarily consist of employee termination costs from the reduction in force commenced in June 2024.
(4)
Represents transaction and integration costs directly related to mergers and acquisitions, including: (i) legal, consulting, and accounting fees associated with acquisitions; (ii) post-acquisition employee retention bonuses; (iii) (gain)/loss from changes in the fair value of contingent consideration liabilities resulting from acquisitions; and (iv) securities litigation costs. Not included in this adjustment are acquired in-process research and development expenses, which totaled zero for both the three months ended March 31, 2026 and 2025, respectively.
MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By
Time Frame
Alert Type
Keywords
Page 1 of 322
Get 30 Days of MarketBeat All Access for Free
Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.
Start Your 30-Day Trial
Sign in to your free account to enjoy these benefits
In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.
Focus 2030 targets market competitiveness and sustainable business operations through brand reinforcement and unification, close partner collaboration, financial discipline, and multi-powertrain strategy.New proprietary X-Hybrid performance technology will be the first of its kind to come to market in Europe in Q4 2026, with more than 1,000 orders in China in the first month for Eletre X - showing early momentum.Type 135 confirmed as an all-new hybrid-V8 supercar coming to market in 2028, reaffirming Lotus’ performance DNA. NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. (“Lotus Tech” or the “Company”) (Nasdaq: LOT), a leading global intelligent and luxury mobility provider, today announced Focus 2030 for Lotus, an evolved business strategy designed to underpin its competitiveness and transformation into a more flexible and sustainable business model ensuring market resilience amid external headwinds.
Built on four core pillars, including brand reinforcement, a multi-powertrain strategy, close partner collaboration, and financial discipline, the strategy marks a significant reset for the brand.
Mr. Qingfeng Feng, Chief Executive Officer of Lotus Tech, said, “Lotus was born from the rebellious spirit of Colin Chapman, and that is not lost today. Focus 2030 will reset both the brand and the business, keeping us true to our DNA. We are obsessed with engineering, performance and building drivers' cars, and that is what will grow this business.”
Protecting What Makes Lotus, Lotus
Focus 2030 puts the Lotus DNA at the heart of every decision. Regardless of product or powertrain, every Lotus has been, and will be, developed against the same set of guiding principles: lightweight design, aerodynamics, obsessive engineering, and driver engagement.
Lotus has been instrumental in shaping automotive culture for 78 years - redefining the limits of performance in racing and building the most engaging road cars in the world. This continues under Focus 2030, with design and engineering rooted in the UK, home of the brand’s identity and motorsport expertise, and R&D in China to deliver rapid scale to market.
Multi-Powertrain Strategy, Built Around the Customer
As regulatory and consumer landscapes continue to evolve globally at different speeds, Lotus will pursue an agile approach across ICE (internal combustion engine), PHEV (hybrid electric vehicle), and BEV (battery electric vehicle), targeting an approximately 60:40 mix between PHEV and BEV volume mix over its electrified portfolio in the interim, and a customer-led transition to full electrification.
Hybrid technology will play a central role, serving specific customer needs. First to come is X-Hybrid, a unique blend of ICE and BEV performance expertise that delivers long-range, flexibility, and practicality alongside sustained high performance and Lotus’ trademark driver engagement.
Lotus’ proprietary X-Hybrid technology was first launched on Eletre, as Eletre X (known as “For Me” in China). Customer deliveries have started in China, and early vehicle reception has been positive, with more than 1,000 orders placed in the first month alone. Customer deliveries in Europe are expected to begin in Q4 2026, making it the first of its kind to come to market.
Reaffirming the brand’s performance DNA, the next development of Lotus’ proprietary hybrid technology will be the unveiling of its first-ever supercar, Type 135 (also known as “Vision X”), planned for delivery in 2028. This will be an all-new car, featuring a V8 hybrid powertrain, with over 1000PS. It is expected to be manufactured in Europe, with further details to be announced later this year.
Emira continuity is confirmed, reflecting both Lotus’ commitment to manufacturing in the UK and sustained consumer demand for its combustion-engine sportscars. The company will reveal an update in the coming weeks, designed to be the most powerful and lightest Emira ever built.
Lotus’ BEV portfolio, Eletre (SUV), Emeya (GT), and Evija (Hypercar), remains a core pillar of the business, having brought new customers to the marque and broadened its commercial foundation. Lotus was an early adopter of 800V architecture through its electric SUV and GT offerings and remains committed to continued BEV innovation.
Built to Compete Globally
Lotus’ close collaboration with its major shareholder, Geely Holding Group, is central to Focus 2030. The two businesses are working together on technology development, supply-chain competitiveness, and manufacturing efficiencies to increase go-to-market speed, global scale, and margin resilience.
The partnership gives Lotus access to world-class electrification capabilities and resources, while Lotus contributes its globally recognized performance engineering expertise and brand equity to Geely Holding Group’s portfolio.
Underpinning this is the planned integration of Lotus UK and Lotus Tech into a single entity, which is expected to unify the brand, streamline governance, reduce costs, and accelerate engineering integration for next-generation performance vehicles.
Daniel Li, Chairman of the Board of Directors at Lotus Tech, and Executive Vice Chairman of Geely Holding Group, said, “Geely has believed in Lotus from the beginning, and that belief has not wavered. We are committed to giving Lotus the resources it deserves to compete at the highest level. What Lotus brings is irreplaceable, and Focus 2030 is proof that we take that responsibility seriously. We are excited for the next chapter in the brand's story."
Restoring Financial Discipline
Focus 2030 sets a clear commercial direction for the business, with a focus on targeted volumes, stronger margins, and greater emphasis on personalization. Lotus is guiding towards a steady ramp-up to 30,000 sales units annually as its full model line-up stabilizes, enabling the business to reach sustained profitability.
Over the last year, Lotus has made significant improvements across its entities to increase operational efficiency. Lotus Tech has also increased cost optimization and operational efficiency, as demonstrated by its improved margins in its full-year 2025 results.
The Company has targeted a clear and diverse strategy across its core markets:
China - the primary volume growth engine, leveraging strong demand for premium new energy vehicles (NEV).Europe - building on racing heritage and British engineering brand equity across a diverse powertrain portfolio.North America - strategy anchored in sports cars, with a new SUV market opportunity in Canada.APAC and Middle East - foundations have been developed, and the brand is now active in 25 markets across the region, providing opportunities to reach new customers with its entire product portfolio. About Lotus Technology Inc.
Lotus Technology Inc. has operations across the UK, the EU and China. The Company is dedicated to delivering luxury lifestyle electric vehicles, with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalization and more. For more information about Lotus Technology Inc., please visit www.group-lotus.com.
Forward-Looking Statements
This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Forward-looking statements involve inherent risks and uncertainties, including those identified under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lotus Technology Inc. undertakes no obligation to update any forward-looking statement, except as required under applicable law.
, /PRNewswire/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and five names sit at the center of that structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).
The trajectory keeps steepening. Analysts project the global POC diagnostics market will reach $114.65 billion by 2035, fueled by AI integration, miniaturized biosensors, and cloud-connected platforms that compress turnaround times from days to minutes[3]. The entire diagnostic equipment value chain is shifting from a centralized hospital model to a decentralized, consumer-facing landscape, and that creates a scalable opening for platforms delivering accessible, clinical-grade outcomes outside traditional hospital walls.
VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.
VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.
That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS ™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.
Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California.
"AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."
With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.
CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/
Other industry developments and happenings in the market include:
Hims & Hers Health (NYSE: HIMS) announced a new collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global consumer health platform for affordable access to approved medications, with prices starting as low as $149 a month.
"Today we're taking an important next step toward building a better model of healthcare that works for everyday people," said Andrew Dudum, co-founder and CEO of Hims & Hers Health. "When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we're thrilled to be working alongside Novo Nordisk to help more people feel their best and we're excited to find more ways to collaborate across the industry."
Novo Nordisk (NYSE: NVO) is expanding patient reach through the partnership, with eligible customers now able to access treatments that can help them lose up to 20% of their body weight. Multiple Wegovy dosing options are available across both injectable and pill formats, alongside Ozempic injection pens approved for Type 2 diabetes treatment.
"Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient," said Dr. Craig Primack, SVP Weight Management at Hims & Hers Health. "As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We're excited to see how our customers succeed as more innovative treatments become available."
MannKind (NASDAQ: MNKD) announced it will present new clinical data on Afrezza at the ATTD 2026 conference in Barcelona, spanning oral and poster sessions focused on real-world dosing patterns and post-prandial glucose management in both adult and pediatric patients with type 1 diabetes. The presentations include findings from the INHALE-1 study, which examined how inhaled insulin is initiated and adjusted in children and adolescents, with patients started at an approximately 2:1 conversion from rapid-acting insulin analogs.
"We look forward to presenting important new data for Afrezza at this year's ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric populations," said Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head, Diabetes for MannKind. "ATTD is a key forum for advancing how clinicians think about insulin use at meals, and we value the opportunity to engage with the global diabetes community on this important topic."
The FDA accepted a supplemental Biologics License Application for Afrezza in patients ages 4-17 living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, Afrezza would become the first needle-free insulin option for pediatric patients in over 100 years.
Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab, a browser-based interface that gives researchers remote access to the company's autonomous lab infrastructure powered by proprietary Reconfigurable Automation Carts. The platform connects scientists to a fleet of over 70 instruments spanning sample preparation, liquid handling, analytical readouts, storage, and incubation, with an AI-driven agent called EstiMate enabling protocol submission in plain language and immediate compatibility assessment and pricing.
"Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports," said Jason Kelly, CEO of Ginkgo Bioworks. "By opening up our autonomous infrastructure through the Cloud Lab, we're giving scientists access to these tools today."
Ginkgo Cloud Lab is central to Ginkgo Bioworks' 2026 strategic shift to consolidate all R&D services onto Nebula, its autonomous lab in Boston, MA, decommissioning traditional benches in favor of programmable robotic infrastructure. The company is targeting users ranging from academic researchers to global biopharmaceutical companies, inviting them to submit protocols directly at cloud.ginkgo.bio for feasibility reports and price quotes.
Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.
Harmonic's SeaStar Optical Node Enables Cost-Effective Broadband Service Expansion in Previously Underserved Brownfield MDU Environments
, /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that DNA Finland, the second largest mobile and fixed broadband operator serving the Finnish market, is expanding multi-gigabit services into lower-density multi-dwelling units (MDUs) with Harmonic's SeaStar™ optical node. The SeaStar node enables DNA Finland to deliver fiber-grade connectivity to brownfield MDU environments that have traditionally been challenging to serve due to permitting complexities and high rewiring costs. By leveraging Harmonic's compact, scalable optical node, DNA Finland can offer competitive, fiber-grade broadband services to the brownfield MDU market, significantly expanding its addressable market beyond the current subscriber base.
"Previously, deploying a dedicated node for every MDU with only a handful of subscribers was cost-prohibitive, making lower-density MDU opportunities economically unviable for us," said Markus Lehtiniemi, access networks design team lead at DNA Finland. "Harmonic's game changing SeaStar node gives us a cost-effective solution to extend high-speed broadband services into the lower-density MDU market we previously could not economically serve. This strengthens our competitive position, establishes a clear market advantage and accelerates business growth."
Harmonic's powerful SeaStar optical node enables DNA Finland to extend multi-gigabit connectivity through a centralized fiber forward architecture that leverages existing in-building coax wiring. The SeaStar node supports up to 16 low-cost optical mini nodes installed at the MDUs via point-to-point fiber connections, which then connect directly to the MDU's existing coax cabling. This helps the operator to reduce infrastructure requirements and lower operational costs while extending reliable high-speed broadband services to more MDUs.
Additionally, the SeaStar node connects seamlessly with Harmonic's Central AI-powered network intelligence and operations service providing DNA Finland with powerful network analytics for real-time network visibility. This enables the proactive resolution of network impairment issues to ensure reliable, consistent broadband service availability.
"DNA Finland's deployment of our SeaStar optical node sets a blueprint for operators looking to overcome the economics of traditional network expansion, enabling them to extend high-quality broadband into MDUs that were previously cost-prohibitive," said Stefan Meier, vice president of broadband sales, Europe at Harmonic. "By combining a compact footprint with scalable performance and operational efficiency, SeaStar allows service providers to unlock new revenue opportunities, improve deployment flexibility and accelerate time to market of new services while maintaining a superior subscriber experience."
Harmonic's market-leading cOS platform powers next-gen broadband services through nearly 46 million CPE devices worldwide for leading operators in North America, Europe, Latin America and Asia. Harmonic will showcase the transformative SeaStar node at ANGA COM, May 19-21 in Cologne, Germany in hall 8, stand C35. To schedule a meeting with Harmonic at ANGA COM, visit www.harmonicinc.com/events/anga-com. To learn more about the SeaStar node, visit www.harmonicinc.com/broadband/seastar-optical-node.
About Harmonic
Harmonic (NASDAQ: HLIT), the worldwide leader in virtualized broadband and video delivery solutions, enables media companies and service providers to deliver ultra-high-quality video streaming and broadcast services to consumers globally. The company revolutionized broadband networking via the industry's first virtualized broadband solution, enabling operators to more flexibly deploy gigabit internet services to consumers' homes and mobile devices. Whether simplifying OTT video delivery via innovative cloud and software platforms, or powering the delivery of gigabit internet services, Harmonic is changing the way media companies and service providers monetize live and on-demand content on every screen. More information is available at www.harmonicinc.com.
Harmonic, the Harmonic logo and other Harmonic marks are owned by Harmonic Inc. or its affiliates. All other trademarks referenced herein are the property of their respective owners.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements concerning Harmonic's business and the anticipated capabilities, advantages, reliability, efficiency, market acceptance, market growth, specifications and benefits of Harmonic products, services and technology are forward-looking statements. These statements are based on our current expectations and beliefs and are subject to risks and uncertainties, including the risks and uncertainties more fully described in Harmonic's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended Dec. 31, 2025, its Quarterly Reports on Form 10-Q and its Current Reports on Form 8-K. The forward-looking statements in this press release are based on information available to Harmonic as of the date hereof, and Harmonic disclaims any obligation to update any forward-looking statements.
Closed sale of the Company's mobile device assets to NEXA in January 2026Completed the transfer of the operations of the phone and hotspot business to NEXAFocused on enhancing the DNA X trading platform to prepare the platform for its initial growth phaseSan Diego, California--(Newsfile Corp. - May 20, 2026) - DNA X, Inc. (NASDAQ: SONM), a provider of cryptocurrency trading services, today announced its financial results for the first quarter ended March 31, 2026.
The company operates the DNA X AI trading platform business, and expects to launch an enhanced version to the public later this year. The platform is designed to harness advanced AI and machine learning technologies to automate intelligent trading strategies, enabling clients to capitalize on data-driven insights and dynamic opportunities.
The Company completed the sale of its mobile device design and manufacturing business to NEXA Mobility, a private company in the hardware space on January 23, 2026. The purchase price of the assets was $15 million less a working capital adjustment of $1.5 million, with $12.0 million being paid immediately and the remaining cash of $1.5 million, less any agreed upon claims, to be paid in October 2026. The company used the proceeds to repay debt and other obligations. The remaining cash will be used to support the DNA X AI trading business.
On January 23, 2026, the Company successfully rebranded itself as DNA X, Inc., from Sonim Technologies Inc. The stock ticker on Nasdaq remains SONM and our primary corporate offices remain in San Diego.
The asset sale resulted in $6.3 million in net income for the first quarter of 2026, net of taxes, transaction fees, and severance costs.
"Having successfully completed a strategic exit from our legacy business, management has made a deterministic decision to reallocate our resources into the high-growth, high-margin decentralized AI and crypto trading sectors," said Mike Mulica, acting Chief Executive Officer. "This pivotal transition marks the beginning of our value build phase, positioning DNA X to deliver sustainable, long-term value for our shareholders through AI and crypto trading innovation."
First Quarter 2026 Financial Highlights:
Revenue: There was no revenue from continuing operations because revenue from our phone and hotspot operations was included in discontinued operations. Our AI platform activities are accounted for as an investment and are reflected as other income.General & Administrative Expenses: First-quarter general and administrative expenses from continuing operations were $3.6 million and included one time severance costs of $1.5 million and $0.9 million in professional services for our annual audit and tax services. We expect general & administrative expenses to be much lower in the next few quarters because we have downsized the organization and we have completed our annual audit. Cash Position: We ended the quarter with $1.2 million in cash from continuing operations. On May 20, 2026 we entered into an agreement to raise an additional $1.8 million in cash by issuing new debt. This cash will be used for working capital purposes and to support and grow the DNA X AI and crypto trading business.About DNA X, Inc. DNA X operates an advanced artificial intelligence platform that automates complex workflows and decision-making using state-of-the-art AI models. For more information, visit https://ir.dna-x.global.
Media and Investor Relations Contact: Clay Crolius, DNA X, Inc. [email protected].
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that do not relate to matters of historical fact are forward-looking statements, including, without limitation, statements regarding the Company's strategic transformation, the expected growth, performance and market opportunities of the DNA X trading platform, anticipated use of proceeds from the sale of the Company's mobile device design and manufacturing business, and the Company's future operations and financial performance.
These forward-looking statements are based on the Company's current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to: risks related to the Company's ability to successfully integrate and operate the DNA X trading platform and achieve anticipated growth; the early-stage nature of the Company's current business and the volatility of the cryptocurrency markets; the Company's recent disposition of its mobile device design and manufacturing business; the Company's ability to obtain or maintain sufficient liquidity to execute its business plan; potential delays or challenges in executing its strategic plans; general economic, market and industry conditions; and the Company's ability to maintain compliance with Nasdaq listing requirements.
Additional information regarding these and other risks and uncertainties is included in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update such statements, except as required by law.
DNA X, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
March 31,
2026
December 31,
2025
(Unaudited)
Assets
Cash and cash equivalents$1,195
$1,303
Receivable for cash held back from the asset sale
1,500
—
Prepaid expenses and other current assets
608
676
Current assets held for sale
—
26,930
Total Current assets
3,303
28,909
Investment in DNA X LLC under equity method
1,290
1,242
Deferred tax assets
—
1,441
Other assets
245
274
Non-current assets held for sale
—
12,032
Total assets$4,838
$43,898
Liabilities and stockholders' deficit
Accounts payable
719
4,030
Accrued liabilities
1,576
704
Promissory note, net from related party
1,072
1,035
Promissory notes, net
—
4,030
Derivative liability
398
171
Income tax payable
556
2,598
Current liabilities held for sale
—
38,057
Total current liabilities
4,321
50,625
Deferred tax liability
600
—
Total liabilities
4,921
50,625
Commitments and contingencies
—
—
Redeemable common stock; $0.001 par value; 223,201 shares issued and outstanding; redemption value $900 at March 31, 2026 and $1,228 as of December 31, 2025 (Note 6)
900
1,228
Stockholders' deficit
Common stock, $0.001 par value per share; 1,000,000,000 shares authorized: and 1,265,067 shares issued and outstanding at both March 31, 2026 and December 31, 2025*
1
1
Preferred stock, $0.001 par value per share, 5,000,000 shares authorized: and no shares issued and outstanding at March 31, 2026 and December 31, 2025
—
—
Additional paid-in capital*
296,613
296,309
Accumulated deficit
(297,597)
(304,265)Total stockholders' deficit
(983)
(7,955)Total liabilities, redeemable common stock, and stockholders' deficit$4,838
$43,898
*Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025.DNA X, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
(UNAUDITED)
Three Months Ended March 31,
2026
2025
Continuing operations:
Net revenues$—
$—
Operating expenses
General and administrative
3,618
870
Total operating expenses
3,618
870
Net loss from operations
(3,618)
(870)Interest expense, net
(131)
(91)Loss on remeasurement of derivative liability
(227)
—
Equity income from DNA X LLC
48
—
Net loss from continuing operations before income taxes
(3,928)
(961)Income tax expense from continuing operations
—
—
Net loss from continuing operations
(3,928)
(961)Discontinued Operations:
Income from discontinued operations, net of tax
10,268
1,419
Net income$6,340
$458
Net earnings (loss) per share basic and diluted:
4.37
Net income*$5.01
$1.41
Weighted-average shares used in computing net loss per share:
Basic and diluted*
1,265,067
324,431
*Adjusted retroactively to reflect the 1-for-18 reverse stock split that became effective on October 28, 2025. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298202
Source: DNA X, Inc. (formerly Sonim Technologies Inc.)
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate ApolloBio's new clinical results further highlight the potential of INOVIO's DNA medicine platform to treat diseases caused by infection with various strains of the human papillomavirus (HPV), eliminating or reducing the need for surgical interventions , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its partner for VGX-3100 in China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being developed as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future regulatory submission of VGX-3100 in China.
"We believe these positive topline results for VGX-3100 reflect both the potential of our DNA medicine platform in HPV-related diseases and the power of partnerships to advance innovative DNA immunotherapies," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We look forward to these data being presented at upcoming international medical conferences and published in peer-reviewed publications. We also anticipate future updates from ApolloBio as they work towards filing for potential regulatory approval of VGX-3100 in China."
According to the terms of the ApolloBio Agreement, INOVIO is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in specified territories. In the event that VGX-3100 is approved for marketing, INOVIO will be entitled to receive royalty payments based on a tiered percentage of annual net sales.
About VGX-3100
VGX-3100 is an innovative therapeutic DNA vaccine developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18. VGX-3100 is designed to elicit an antigen-specific, CD8+ T cell response to clear persistent HPV 16/18 infection, thereby promoting lesion regression and viral clearance.
INOVIO licensed VGX-3100 to ApolloBio in 2018 for Greater China. ApolloBio's first intended indication for VGX-3100 is HPV-16/18-associated cervical dysplasia, with the aim of potentially providing patients in China with a non-surgical therapeutic option that may help avoid or reduce fertility-related risks associated with conventional surgical treatment (such as LEEP/conization), including preterm birth and miscarriage. ApolloBio is also advancing clinical development in other HPV-related high-grade precancerous lesions, including anal/perianal, vulvar, and vaginal disease.
About ApolloBio's Phase 3 Trial with VGX-3100
The study, sponsored by ApolloBio, is a multicenter, prospective, randomized, double-blind, placebo-controlled Phase 3 pivotal registrational clinical trial for the treatment of HPV-16/18-associated cervical high-grade squamous intraepithelial lesions (HSIL), or cervical dysplasia. The primary endpoint was the composite response rate at Week 36, defined as histopathologic regression of cervical disease to low-grade lesion (CIN1) or normal histology, together with clearance of HPV-16 and/or HPV-18 infection. The study was led by Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Lingying Wu serving as the leading principal investigator. A total of 22 top-tier tertiary hospitals across China participated in the trial.
ApolloBio announced that the trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile, with no new significant safety risk signals observed. The positive outcome of this study provides important clinical evidence to support ApolloBio's future regulatory submission of VGX-3100 in China.
About HPV, Cervical Cancer, and Cervical Dysplasia
HPV is the most common sexually transmitted infection and is the main cause of cervical cancer, which is the fourth most common cancer in women globally with around 660,000 new cases and 350,000 deaths in 2022. Two types of HPV (HPV 16 and HPV 18) collectively cause about 70 percent of cervical cancer cases worldwide. High-grade cervical dysplasia is also caused by persistent HPV infection and is a precancerous condition that can progress to cervical cancer if left untreated. Currently there are no US-approved therapeutic treatments for persistent HPV infection or cervical dysplasia.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
About ApolloBio
ApolloBio Corp. is a leading Chinese biomedical company committed to research and development of innovative new medicines, accessing such new medicines through in-licensing, and additionally providing medical services. ApolloBio Corp. is focused on pharmaceutical products with significant market potential in China in the field of oncology; providing efficient access for American biomedical companies to enter into the Chinese market; and aiming to bring the newest and best medicines across the globe to the Chinese people. For more information, visit www.apollobio.com.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the potential of VGX-3100 for the treatment of cervical dysplasia, including the reproducibility of the clinical trial results in any future trials and the success of any future regulatory submission; the potential of INOVIO's DNA medicine platform in HPV-related diseases; our ability to establish and maintain development partnerships; and our expectations regarding future milestone or royalty payments. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification
, /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management. The launch builds on the three companies' strategic partnership, announced in August 2025, to deploy AI-driven, lab-in-the-loop workflows across the biopharma industry.
ADME-One is designed to break a cycle that has constrained small molecule drug discovery for decades: Due to the economic limitations of traditional data generation methods, comprehensive ADME profiling is typically reserved for lead optimization after teams have determined their lead series. When liabilities surface at this later stage, the cost of fixing them is highest. ADME-One changes that calculus, allowing discovery teams to characterize entire series with integrated, data-driven decisions in stages as early as hit identification. The result is fewer surprises, fewer wasted synthesis cycles, and a better ability to identify and test the compounds most likely to succeed in humans.
A Single, Integrated Workflow Across Three Category Leaders
ADME-One unites three best-in-class capabilities in one packaged service:
Ginkgo Datapoints: Data Generation. All five Tier 1 assays (microsomal stability, cell permeability, kinetic solubility, CYP inhibition, and plasma protein binding) are executed end-to-end in Ginkgo's automated laboratory in Boston. Validated, standardized workflows produce AI-ready data without the variability of manual handling. Inductive Bio: AI-Driven Contextualization. Inductive Bio's Compass platform turns the experimental panel into actionable human PK projections, integrating disparate individual ADME datapoints into a single multiparameter optimization endpoint that guides compound prioritization. The company's ADMET models are independently validated as best-in-class, having recently won both the 2025 ASAP and 2026 ExpansionRx OpenADMET blind prediction challenges, two of the most rigorous public benchmarks in the field. Tangible Scientific: Compound Management. Customers submit compounds and receive results. Tangible handles compound intake, plating, real-time tracking, and management for every ADME-One order, eliminating the logistics overhead that typically accompanies outsourced ADME work. Impact on Drug Discovery
"With ADME-One, we're both lowering the price of an ADME panel and transforming when and to what extent this data is effectively used in the drug discovery process," said John Androsavich, General Manager at Ginkgo Datapoints. "For the first time, chemists can efficiently characterize the entire series in hit identification. That fundamentally changes the quality of decisions teams make at the earliest stages of a program, where derisking is most needed. By combining automation, AI, and integrated logistics in a single domestic workflow, Ginkgo and our partners are demonstrating and making available the workflows that the Bio × AI era of drug discovery demands."
"We are at a moment in the application of AI to medicine where discovery teams can generate and prioritize drug candidates faster than their physical operations can validate them. Manifests get reconciled by hand, orders move through email threads, and senior scientists spend hours per week chasing shipments and tracking inventory across vendors. Tangible's role in ADME-One is to make the handoffs between design and data disappear, so discovery teams can validate candidates at the speed their AI investments promised," said Adham Chebbani, Co-founder of Tangible Scientific.
"The question every drug program is really trying to answer is which compound is most likely to achieve a safe and efficacious human dose," said Josh Haimson, CEO at Inductive Bio. "The Inductive platform lets drug hunters rank millions of compounds by predicted human dose, using state-of-the-art AI models that placed first in both OpenADMET competitions. With ADME-One, we move those compounds from the virtual lab to the wet lab in a tight feedback loop, surfacing the most promising ideas from day one. This is what AI-driven discovery looks like in practice: better decisions earlier, fewer dead ends later, and higher-quality medicines reaching patients sooner."
Together, the three partners deliver unified, contextualized ADME data in a streamlined workstream with rapid turnaround, all at a price point several times lower than the industry standard. Against the backdrop of U.S. and European drug developers reshoring preclinical efforts in response to the BIOSECURE Act and growing demand for data sovereignty, ADME-One delivers a fully U.S.-based workflow at pricing that beats offshore alternatives. Automated workflows return results in days rather than weeks, and because every run is standardized, each screening campaign contributes to better future predictions, delivering the volume, consistency, and metadata richness that AI-driven discovery depends on.
To drive ADME-One's product strategy, Ginkgo Datapoints has added Jonathan Grob to its leadership team as Vice President of Small Molecules. Grob brings deep expertise in medicinal chemistry, automation, and technology development from prior roles at Novartis and Valo Health. His hire reflects Ginkgo's continued investment in building the strongest next-generation, AI-enabled small molecule drug discovery team in the industry, complementing the platform's automation and data generation capabilities with seasoned scientific leadership.
Get Started on ADME-One
Drug discovery teams interested in early access or volume engagements are encouraged to contact Ginkgo Datapoints, Tangible Scientific, or Inductive Bio directly. Existing customers can contact their account representative to enable access to ADME-One. New customers can email [email protected] and visit our website at https://datapoints.ginkgo.bio/services#small-molecule-adme
The three partners host the New England Drug Metabolism Discussion Group (NEDMDG) meeting on May 27 in Boston where they will share additional technical details, validation data, and customer case studies.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "Cloud Lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com, read our blog, or follow us on social media channels such as X (@Ginkgo), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
About Tangible Scientific
Tangible Scientific is a tech-enabled compound management platform that removes the logistics bottleneck between design and data. From its Natick, MA facility, Tangible takes operational custody of customer compounds, handling storage, reformatting, plating, and same-day courier service to Boston-area partners including Ginkgo. AI-powered manifest reconciliation, real-time order tracking, and structured data return run through a single interface, giving discovery teams the quality of an in-house compound operation without the cost of building one. For more information, visit tangiblescientific.com.
About Inductive Bio
Inductive builds virtual chemistry labs that help drug hunters design higher quality molecules, faster. Inductive's virtual labs are designed to scale proven scientific best practices across medicinal chemistry, computational chemistry, DMPK, and safety, enabling teams to make higher-quality decisions consistently throughout discovery. Inside these virtual labs, AI chemistry assistants, predictive ADMET and PK models, and human-relevant digital organ technologies work together to help scientists evaluate more hypotheses in silico and surface key risks earlier. The most promising molecules move from the virtual lab to the wet lab in a tight feedback loop that accelerates the advancement of high-quality molecules. Inductive already powers dozens of active discovery programs, including collaborations with leading biopharma partners. For more information, please visit www.inductive.bio.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous labs. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our platform programs and assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies, including potential adverse effects from the U.S. government shutdown. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 26, 2026, and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform. With this expanded label, Tempus is the first laboratory to hold FDA companion diagnostic (CDx) approval for both tumor-only and tumor-normal comprehensive genomic profiling.
Tempus xT CDx is a 648-gene tissue-based assay intended for molecular profiling of all solid tumor malignancies. It also serves as a companion diagnostic to identify colorectal cancer patients who may benefit from targeted therapies, specifically Erbitux® (cetuximab) and Vectibix® (panitumumab).
While xT CDx previously required a patient’s matched normal sample, this regulatory milestone allows the test to run as a tumor-only assay when a matched normal specimen (blood or saliva) is not viable or available. This approval paves the way for Tempus to migrate its entire DNA solid tumor portfolio to FDA-approved assays priced under its current ADLT (Advanced Diagnostic Laboratory Test) pricing.
“This approval marks a milestone in both our regulatory and reimbursement strategy, as this allows the migration of our entire solid tumor DNA portfolio to be under unified ADLT pricing,” said Jim Rogers, Chief Financial Officer at Tempus. “As we have previously highlighted, we expect an estimated $200 ASP benefit beginning in 2027 as a result of this approval.”
“Our goal is to support clinicians with advanced genomic profiling options,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “With FDA approval for both tumor-only and tumor-normal comprehensive genomic profiling, Tempus xT CDx provides flexibility for a range of clinical scenarios. While tumor-normal matched sequencing remains an important approach, we recognize that a matched sample is not always available, and now, patients can still benefit from an FDA-approved test that can help inform treatment decisions.”
xT CDx is a qualitative Next Generation Sequencing (NGS)-based in vitro diagnostic device intended for use in the detection of substitutions (single nucleotide variants (SNVs) and multi-nucleotide variants (MNVs)) and insertion and deletion alterations (INDELs) in 648 genes in patients with previously diagnosed solid malignant neoplasms. The assay uses DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and, when available, patient-matched blood or saliva specimens. Additionally, the device detects microsatellite instability (MSI) status based on a genomic signature from the tumor specimen only. The test is intended as a companion diagnostic (CDx) to identify patients who may benefit from treatment with the targeted therapies listed in the Companion Diagnostic Indications table in accordance with the approved therapeutic product labeling. Additionally, xT CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with previously diagnosed solid malignant neoplasms. Genomic findings other than those listed in the Companion Diagnostic Indications table are not prescriptive or conclusive for labeled use of any specific therapeutic product.
Click to view the complete xT CDx label, including companion diagnostic indications and important risk information.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding potential impact of xT CDx and other tests, the timing of the availability of such testing, and the potential financial impact of migrating our solid tumor portfolio to FDA approved assays. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
